CN101914133B - 一种21(s)阿加曲班的定向合成方法 - Google Patents
一种21(s)阿加曲班的定向合成方法 Download PDFInfo
- Publication number
- CN101914133B CN101914133B CN 201010252144 CN201010252144A CN101914133B CN 101914133 B CN101914133 B CN 101914133B CN 201010252144 CN201010252144 CN 201010252144 CN 201010252144 A CN201010252144 A CN 201010252144A CN 101914133 B CN101914133 B CN 101914133B
- Authority
- CN
- China
- Prior art keywords
- argatroban
- methyl
- arginyl
- nitro
- synthesis method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 title claims abstract description 73
- 229960003856 argatroban Drugs 0.000 title claims abstract description 71
- 238000001308 synthesis method Methods 0.000 title claims abstract description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 12
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 4
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 3
- 229960000583 acetic acid Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 230000008034 disappearance Effects 0.000 claims description 2
- 239000012362 glacial acetic acid Substances 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 238000006555 catalytic reaction Methods 0.000 abstract 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 abstract 1
- FPEIMKAERNJXBH-UHFFFAOYSA-N ethyl formate;hydrochloride Chemical compound Cl.CCOC=O FPEIMKAERNJXBH-UHFFFAOYSA-N 0.000 abstract 1
- 235000019253 formic acid Nutrition 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- AIEZTKLTLCMZIA-CZSXTPSTSA-N (2r,4r)-1-[(2s)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid;hydrate Chemical compound O.OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2 AIEZTKLTLCMZIA-CZSXTPSTSA-N 0.000 description 30
- 241000282472 Canis lupus familiaris Species 0.000 description 28
- 230000000694 effects Effects 0.000 description 23
- 239000013078 crystal Substances 0.000 description 18
- 229940033590 argatroban injection Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 230000023555 blood coagulation Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 108090000190 Thrombin Proteins 0.000 description 9
- 229960004072 thrombin Drugs 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 6
- 108010094028 Prothrombin Proteins 0.000 description 5
- 102100027378 Prothrombin Human genes 0.000 description 5
- 229940039716 prothrombin Drugs 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- -1 aminoiminomethyl Chemical group 0.000 description 4
- 238000002447 crystallographic data Methods 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940122388 Thrombin inhibitor Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000003868 thrombin inhibitor Substances 0.000 description 3
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical group Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 2
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000004455 differential thermal analysis Methods 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- UQHCHLWYGMSPJC-UHFFFAOYSA-N 4-methylpiperidin-1-ium-2-carboxylate Chemical compound CC1CCNC(C(O)=O)C1 UQHCHLWYGMSPJC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010029144 Factor IIa Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 108010072035 antithrombin III-protease complex Proteins 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010252144 CN101914133B (zh) | 2008-03-07 | 2008-03-07 | 一种21(s)阿加曲班的定向合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010252144 CN101914133B (zh) | 2008-03-07 | 2008-03-07 | 一种21(s)阿加曲班的定向合成方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008100523831A Division CN101235031A (zh) | 2008-03-07 | 2008-03-07 | 21(s)阿加曲班定向合成和晶体结构及一水合物的制备 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101914133A CN101914133A (zh) | 2010-12-15 |
CN101914133B true CN101914133B (zh) | 2013-01-30 |
Family
ID=43321799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010252144 Active CN101914133B (zh) | 2008-03-07 | 2008-03-07 | 一种21(s)阿加曲班的定向合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101914133B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104558103B (zh) * | 2013-10-24 | 2019-02-26 | 四川科瑞德制药股份有限公司 | 一种阿加曲班中间体的制备方法 |
CN105837658B (zh) * | 2016-04-27 | 2019-08-27 | 河北国龙制药有限公司 | 一种阿加曲班的合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0008746A1 (en) * | 1978-08-31 | 1980-03-19 | Mitsubishi Kasei Corporation | Alpha-(N-arylsulfonyl-L-argininamides, processes for their preparation and pharmaceutical compositions containing these substances |
CN1951916A (zh) * | 2006-11-10 | 2007-04-25 | 天津市炜杰科技有限公司 | 阿加曲班中间体的制备方法 |
-
2008
- 2008-03-07 CN CN 201010252144 patent/CN101914133B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0008746A1 (en) * | 1978-08-31 | 1980-03-19 | Mitsubishi Kasei Corporation | Alpha-(N-arylsulfonyl-L-argininamides, processes for their preparation and pharmaceutical compositions containing these substances |
CN1951916A (zh) * | 2006-11-10 | 2007-04-25 | 天津市炜杰科技有限公司 | 阿加曲班中间体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101914133A (zh) | 2010-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103221414B (zh) | 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途 | |
CN108473524B (zh) | 一种泰拉霉素的制备方法及其中间体 | |
CN109111501A (zh) | 脂肪氨基酸修饰的吲哚乙醇衍生物,其合成,活性和应用 | |
CN101235031A (zh) | 21(s)阿加曲班定向合成和晶体结构及一水合物的制备 | |
CN105753701B (zh) | 一种双效麻醉药物及其制备方法和用途 | |
CN101914133B (zh) | 一种21(s)阿加曲班的定向合成方法 | |
CN1907954B (zh) | 麻醉药2,6-二异丙基苯酚的水溶性衍生物及其制备方法 | |
CN108395437B (zh) | 氘代化合物及其医药用途 | |
ES2593578T3 (es) | Derivado de butilftalida y método de preparación y uso del mismo | |
CN106518750A (zh) | 咔唑氨基醇类化合物及其制备方法和抗寄生虫病的用途 | |
CN101914132A (zh) | 21(s)阿加曲班的晶体结构 | |
CN103360462A (zh) | 一种丙氨酰谷氨酰胺原料药的精制方法 | |
CN102558170B (zh) | 一种光学纯顺式阿扑长春胺酸酯类的制备方法 | |
CN103044467B (zh) | 一种制备用于合成硼替佐米的中间体的方法 | |
CN104761610A (zh) | 一类新型的α-常春藤皂苷衍生物及其制备方法和用途 | |
CN107556167A (zh) | 一种麻醉类化合物及其制备方法和用途 | |
CN106883282B (zh) | 救必应酸衍生物在制备抗肿瘤的药物中的应用 | |
CN102180878B (zh) | 一种多拉司琼异构体或其盐及其制备方法和其应用 | |
CN101597276B (zh) | N-(α,β-二巯基-β-羧基丙酰基)-氨基酸的丙叉衍生物及其合成方法和应用 | |
CN1318414C (zh) | 含邻萘醌结构的化合物及其应用 | |
ES2528045T3 (es) | Nuevo derivado de síntesis de la ecdisterona, procedimiento de preparación y utilización del mismo | |
CN102503897A (zh) | 一种5-氟尿嘧啶碘化油衍生物及其制备方法和用途 | |
CN104447753B (zh) | 一种西他列汀及其中间体的制备方法 | |
CN109096191A (zh) | 氟比洛芬美普他酚酯药用化合物及其制备方法 | |
CN110684066B (zh) | 胞二磷胆碱药物制剂及其脑梗塞急性期意识障碍的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Directed synthesis method of 21 (S) group Effective date of registration: 20140826 Granted publication date: 20130130 Pledgee: Bank of Tianjin, Limited by Share Ltd, Hongqiao branch Pledgor: Tianjin Weijie Technology Co., Ltd. Registration number: 2014990000704 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150724 Granted publication date: 20130130 Pledgee: Bank of Tianjin, Limited by Share Ltd, Hongqiao branch Pledgor: Tianjin Weijie Technology Co., Ltd. Registration number: 2014990000704 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Directed synthesis method of 21 (S) group Effective date of registration: 20150727 Granted publication date: 20130130 Pledgee: Bank of Tianjin, Limited by Share Ltd, Tianma subbranch Pledgor: Tianjin Weijie Technology Co., Ltd. Registration number: 2015990000619 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Directed synthesis method of 21 (S) group Effective date of registration: 20160726 Granted publication date: 20130130 Pledgee: Bank of Tianjin, Limited by Share Ltd, Tianma subbranch Pledgor: Tianjin Weijie Technology Co., Ltd. Registration number: 2016990000637 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160725 Granted publication date: 20130130 Pledgee: Bank of Tianjin, Limited by Share Ltd, Tianma subbranch Pledgor: Tianjin Weijie Technology Co., Ltd. Registration number: 2015990000619 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170724 Granted publication date: 20130130 Pledgee: Bank of Tianjin, Limited by Share Ltd, Tianma subbranch Pledgor: Tianjin Weijie Technology Co., Ltd. Registration number: 2016990000637 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Directed synthesis method of 21 (S) group Effective date of registration: 20170726 Granted publication date: 20130130 Pledgee: Bank of Tianjin, Limited by Share Ltd, Tianma subbranch Pledgor: Tianjin Weijie Technology Co., Ltd. Registration number: 2017990000686 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180725 Granted publication date: 20130130 Pledgee: Bank of Tianjin, Limited by Share Ltd, Tianma subbranch Pledgor: Tianjin Weijie Technology Co., Ltd. Registration number: 2017990000686 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Directed synthesis method of 21 (S) group Effective date of registration: 20180725 Granted publication date: 20130130 Pledgee: Bank of Tianjin, Limited by Share Ltd, Tianma subbranch Pledgor: Tianjin Weijie Technology Co., Ltd. Registration number: 2018990000599 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180730 Granted publication date: 20130130 Pledgee: Bank of Tianjin, Limited by Share Ltd, Tianma subbranch Pledgor: Tianjin Weijie Technology Co., Ltd. Registration number: 2018990000599 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Directed synthesis method of 21 (S) group Effective date of registration: 20180730 Granted publication date: 20130130 Pledgee: Bank of Tianjin, Limited by Share Ltd, Tianma subbranch Pledgor: Tianjin Weijie Technology Co., Ltd. Registration number: 2018990000622 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PM01 | Change of the registration of the contract for pledge of patent right | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20210719 Registration number: 2018990000622 Pledgee after: Bank of Tianjin Co.,Ltd. second center sub branch Pledgee before: Bank of Tianjin Limited by Share Ltd. Tianma subbranch |